Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Elsevier to provide Reaxys access to Pharmaron
Reaxys is a web-based chemistry workflow solution which supports research and fuels discovery by integrating searches for reaction and substance data with synthesis planning and chemical sourcing. The
Reaxys is a web-based chemistry workflow solution which supports research and fuels discovery by integrating searches for reaction and substance data with synthesis planning and chemical sourcing. The
Tekmira has demonstrated multi-gene knockdown using MV-RNA enabled by proprietary LNP formulations. Under the collaboration, both the companies will work together to develop and design MV-RNA molecules to
The results of the trial demonstrated that BioThrax plus CPG 7909 generated antibody responses that were 6-fold higher than those generated by BioThrax alone (232µg/ml with BioThrax alone;
Yates will report to Bernd Reckmann, member of the executive board of Merck and is responsible for the Chemicals business sector, which includes the Merck Millipore and Performance
The new corporate centre, which is expected to be ready for occupancy at the end of 2013, is said to create more than 300 jobs during the construction
The purchase price includes a sum of $4m for shares in BMM Pharma and approximately $2m for the inventory. The acquisition allows Bluefish to increase the value of
The company expects to recruit around 100 people in this 260,000sq² facility which will be engaged in manufacturing with both committed (fixed) production lines and flexible manufacturing areas.
The collaboration will deliver drug-development candidates by combining Bend’s problem-solving and formulation or processing expertise for delivering poorly soluble compounds with Xcelience’s early-phase development activities. The program will
The company has posted a net income of RMB14.14m for the second quarter of 2011, compared to RMB19.39m for the same period in 2010. China Nuokang has generated
Under the deal, both the firms will jointly evaluate certain AH proprietary probiotic technology to develop as a treatment or management of gastrointestinal (GI) conditions. Following the completion